Propanc Biopharma (PPCB) Convertible Debt (2014 - 2025)
Propanc Biopharma (PPCB) posted quarterly Convertible Debt of $65280.0 for Q4 2025, down 56.31% year-over-year from $149400.0 in Q4 2024, and little changed quarter-over-quarter from $65280.0 in Q3 2025.
Propanc Biopharma (PPCB) Convertible Debt (2014 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Convertible Debt for 12 consecutive years, with $65280.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Convertible Debt fell 56.31% year-over-year to $65280.0; the TTM figure through Dec 2025 stood at $65280.0 (down 56.31% YoY), while the FY2025 annual figure was $65280.0, changed 0.0% from the prior year.
- Convertible Debt held at $65280.0 in Q4 2025 per PPCB's latest filing, from $65280.0 in the prior quarter.
- Across five years, Convertible Debt topped out at $211650.0 in Q1 2025 and bottomed at $65280.0 in Q3 2023.
- Historically, Convertible Debt has averaged $98425.5 across 5 years, with a median of $80000.0 in 2021.
- Annual changes were most pronounced in 2021 — Convertible Debt surged 841.18% — and 2023, when it slumped 60.32%.
- Propanc Biopharma's Convertible Debt stood at $80000.0 in 2021, then jumped by 105.62% to $164500.0 in 2022, then plunged by 60.32% to $65280.0 in 2023, then jumped by 128.86% to $149400.0 in 2024, then slumped by 56.31% to $65280.0 in 2025.
- Business Quant data shows PPCB's Convertible Debt at $65280.0 in Q4 2025, $65280.0 in Q3 2025, and $65280.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - |
| 10 | Propanc Biopharma | 566,478.81 | 566,478.81 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 65,280.00 |
| Sep 30, 2025 | 65,280.00 |
| Jun 30, 2025 | 65,280.00 |
| Mar 31, 2025 | 211,650.00 |
| Dec 31, 2024 | 149,400.00 |
| Sep 30, 2024 | 145,700.00 |
| Jun 30, 2024 | 65,280.00 |
| Mar 31, 2024 | 65,280.00 |
| Dec 31, 2023 | 65,280.00 |
| Sep 30, 2023 | 65,280.00 |
| Jun 30, 2023 | 75,300.00 |
| Mar 31, 2023 | 121,500.00 |
| Dec 31, 2022 | 164,500.00 |
| Sep 30, 2022 | 164,500.00 |
| Jun 30, 2022 | 79,000.00 |
| Mar 31, 2022 | 80,000.00 |
| Dec 31, 2021 | 80,000.00 |
| Sep 30, 2021 | 80,000.00 |
| Jun 30, 2021 | 80,000.00 |
| Mar 31, 2021 | 80,000.00 |